Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tineacide is a topical antifungal solution developed and manufactured by Blaine Labs Inc. (Blaine Company). Its active ingredient is 1% tolnaftate, a synthetic thiocarbamate small molecule. Tolnaftate works by inhibiting fungal squalene epoxidase, an enzyme essential for the synthesis of ergosterol. The resulting depletion of ergosterol and accumulation of squalene disrupts the integrity of the fungal cell membrane, leading to cell death. The product is formulated as an oil-based solution containing oil of oregano (carvacrol), safflower oil, jojoba oil, and mineral oil to assist in delivery. Tineacide is FDA-approved for the over-the-counter treatment of superficial dermatophyte infections, including tinea pedis (athlete's foot), tinea corporis (ringworm), tinea cruris (jock itch), and onychomycosis (nail fungus).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tineacide.